Search results for "LIPOPROTEIN"

showing 10 items of 982 documents

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with …

2012

Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg across subgroups of subjects with (n = 617) and without (n = 191) metabolic syndrome (MetS). Methods This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18–79 years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. Results In subjects with M…

Blood GlucoseMaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologyEndocrinologyAtorvastatinMedicineRosuvastatin CalciumMetabolic SyndromeSulfonamidesAnticholesteremic AgentsFastingMiddle AgedDrug CombinationsTreatment OutcomeTolerabilityCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyDrug Administration ScheduleEzetimibeDouble-Blind MethodDiabetes mellitusInternal MedicineHumansRosuvastatinPyrrolescardiovascular diseasesAgedApolipoproteins Bbusiness.industrynutritional and metabolic diseasesCholesterol LDLmedicine.diseaseFluorobenzenesDiabetes Mellitus Type 1PyrimidinesDiabetes Mellitus Type 2SimvastatinHeptanoic AcidsAzetidinesMetabolic syndromebusinessDiabetic AngiopathiesDiabetes, obesitymetabolism
researchProduct

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomized, double-blind, placebo-controll…

2009

High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentration…

Blood GlucoseMalemedicine.medical_specialtyBrachial ArteryVasodilator AgentsAdministration OralCoronary Artery DiseasePlaceboNiacinGastroenterologyCoronary artery diseaseNitroglycerinchemistry.chemical_compoundHigh-density lipoproteinDouble-Blind MethodInternal medicinemedicine.arterymedicineHumansProspective StudiesPhosphorylationEndothelial dysfunctionBrachial arteryTriglyceridesAgedUltrasonographyVascular diseasebusiness.industryCholesterol HDLMicrofilament Proteinsnutritional and metabolic diseasesCholesterol LDLMiddle AgedPhosphoproteinsmedicine.diseaseVasodilationB vitaminsTreatment OutcomeEndocrinologychemistryDelayed-Action PreparationsFemalelipids (amino acids peptides and proteins)Endothelium VascularCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesBiomarkersNiacinAtherosclerosis
researchProduct

Plasma glycosphingolipids in diabetics and normals

1975

In diabetic patients with hyperlipoproteinemia type IV the monohexosyl ceramide concentration in blood plasma is significantly elevated. This augmentation can be attributed to an increased monohexosyl ceramide content of the BLDL plasma fraction. In contrast, the di-, tri-, the tetrahexosyl ceramide levels remain within normal limits. In normolipidemic diabetics of comparable age, sex, and weight classes and of comparable metabolic control no elevations of glycolipid fractions could be found. However, patients with primary hyperlipoproteinemia type IV show an increase of monohexosyl ceramide concentrations in blood plasma. Therefore, the augmentation of monohexosyl ceramide levels in plasma…

Blood GlucoseMalemedicine.medical_specialtyCeramideVery low-density lipoproteinHyperlipidemiasLipoproteins VLDLCeramidesGlycosphingolipidsDiabetes Complicationschemistry.chemical_compoundGlycolipidInternal medicineDiabetes mellitusDrug DiscoveryBlood plasmaDiabetes MellitusmedicineHumansObesityTriglyceridesGenetics (clinical)HexosesChemistrynutritional and metabolic diseasesGeneral MedicineMiddle Agedmedicine.diseaseMolecular medicineNormal limitEndocrinologyMetabolic control analysisMolecular MedicineFemaleGlycolipidsKlinische Wochenschrift
researchProduct

Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome

2009

Summary Objective  Small, dense low-density lipoproteins (LDL) are a feature of the metabolic syndrome (MS) but their predictive role still remains to be established. We performed a 2-year follow-up study in 124 subjects with MS (63 ± 6 years), as defined by the American Heart Association/National Heart, Lung and Blood Institute guidelines, to assess clinical and biochemical predictors of cerebro- and cardio-vascular events. Methods and results  Beyond traditional cardiovascular risk factors, we measured LDL size and subclasses by gradient gel electrophoresis. Clinical events were registered in the 25% of subjects. At univariate analysis subjects with events had increased prevalence of elev…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthCerebroCoronary artery diseaseEndocrinologyPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansFamily historyLow-density lipoproteins (LDL metabolic syndromeAgedMetabolic SyndromeUnivariate analysisbusiness.industryMiddle Agedmedicine.disease1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologymedicine.anatomical_structureSmall dense low-density lipoproteins cardio events cerebro-vascular events the metabolic syndromeCardiovascular DiseasesPredictive value of testsCirculatory systemFemaleMetabolic syndromebusinessBlood vesselFollow-Up Studies
researchProduct

Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response

2000

Objectives: The aim of the present study was to evaluate the effects of pravastatin treatment on lipid, inflammation, and coagulation parameters in patients suffering from myocardial infarction with or without carotid atherosclerotic lesions (groups 1 and 2, respectively). Methods: In the first phase of the study, a cross-sectional comparison of lipid, inflammation, and coagulation parameters was performed between the patients and the control group (group 3). Highly significant differences in these parameters were observed, especially in group 1. In the second phase of the study, we assessed the effects of a persistent reduction in cholesterol synthesis induced by increasing doses of pravas…

Blood GlucoseMalemedicine.medical_specialtyMyocardial InfarctionInflammationCoronary Artery DiseaseFibrinogenchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumansPharmacology (medical)PravastatinInflammationPharmacologyDose-Response Relationship DrugFactor VIIbusiness.industryCholesterolpravastatin inflammatory responseGeneral MedicineMiddle AgedBlood Coagulation FactorsCholesterolCross-Sectional StudiesEndocrinologyCoagulationchemistryCase-Control StudiesHemostasisFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptombusinessPravastatinmedicine.drugLipoproteinEuropean Journal of Clinical Pharmacology
researchProduct

Effects of Strength Training and Reduced Training on Functional Performance and Metabolic Health Indicators in Middle-Aged Men

2007

Changes in muscular fitness and metabolic health indicators were examined in 22 men (57.9 +/- 6.6 years, BMI 24.5 +/- 2.6 kg/m (2)) and 21 control men (58.2 +/- 6.1 years, BMI 25.4 +/- 2.8 kg/m (2)) during two consecutive 21-week periods: 1) whole body progressive strength training (ST: twice a week), and 2) continued reduced training (CRT: 3 ST sessions/2 weeks, n = 17 + 17). After the 21-week ST period, maximal strength of leg extensors increased in the ST group by 19.6 +/- 7.6 % vs. 2.8 +/- 4.4 % (p < 0.001) and also 10-m walking time and 10-step stair-climbing time shortened by - 17.2 +/- 7.6 % vs. 4.1 +/- 3.9 % (p < 0.01) and by - 8.2 +/- 6.8 % vs. - 3.0 +/- 6.8 % (p < 0.05) compared t…

Blood GlucoseMalemedicine.medical_specialtyWeight LiftingStrength trainingHealth StatusLipoproteinsPhysical fitnessDiastoleBlood sugarHemodynamicsBlood PressurePhysical Therapy Sports Therapy and RehabilitationAnimal scienceHumansMedicineOrthopedics and Sports MedicineFinlandMetabolic healthbusiness.industryFeeding BehaviorMiddle AgedSurgeryBlood pressurePhysical FitnessMuscle strengthbusinessInternational Journal of Sports Medicine
researchProduct

Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease.

1997

The minimum model modified by the administration of insulin provides an objective and relatively easily measured index of peripheral sensitivity to insulin which was significantly lower (p <0.02) in familial combined hyperlipidemia (FCH) with ischemic heart disease (IHD) than in FCH without IHD and in control subjects (1.2 +/- 0.6, 1.9 +/- 1.0, 2.9 +/- 1.2 x 10(-4) mU/L/ min, respectively). In patients with FCH, insulin resistance explains, at least in part, their metabolic alterations (hypertension, abnormal glucose tolerance, hyperinsulinemia) and elevated IHD.

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentLipoproteinsHyperlipidemia Familial CombinedCoronary DiseaseDiseaseCoronary artery diseaseInsulin resistanceRisk FactorsInternal medicineHyperinsulinemiaMedicineHumansInsulinIn patientcardiovascular diseasesbusiness.industryInsulinGlucose Tolerance TestMiddle Agedmedicine.diseasePeripheralPedigreeEndocrinologyPhenotypeCardiologyInsulin ResistanceCardiology and Cardiovascular MedicinebusinessLipoproteinThe American journal of cardiology
researchProduct

Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial.

2013

Summary Background & aims Epidemiological data suggest that moderate red wine consumption reduces cardiovascular mortality and the incidence of diabetes. However, whether these effects are due to ethanol or to non-alcoholic components of red wine still remains unknown. The aim of the present study was to compare the effects of moderate consumption of red wine, dealcoholized red wine, and gin on glucose metabolism and the lipid profile. Methods Sixty-seven men at high cardiovascular risk were randomized in a crossover trial. After a run-in period, all received each of red wine (30 g alcohol/d), the equivalent amount of dealcoholized red wine, and gin (30 g alcohol/d) for 4 week periods, in a…

Blood GlucoseMalemedicine.medical_treatmentWineCarbohydrate metabolismCritical Care and Intensive Care Medicinechemistry.chemical_compoundInsulin resistanceFolic AcidAdipokinesRisk FactorsDiabetes mellitusmedicineHomeostasisHumansInsulinFood scienceHomocysteineTriglyceridesAgedWineNutrition and DieteticsCross-Over Studiesmedicine.diagnostic_testEthanolCholesterolbusiness.industryInsulindigestive oral and skin physiologyfood and beveragesPolyphenolsFastingMiddle Agedmedicine.diseaseDietVitamin B 12ApolipoproteinsCholesterolGlucosechemistryCardiovascular DiseasesInsulin ResistancebusinessLipid profileLipoproteinClinical nutrition (Edinburgh, Scotland)
researchProduct

Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women

2008

Summary Objective  The aim of the present study was to determine if the favourable cardiopulmonary and metabolic benefits induced by exercise training (ET) programme are maintained after its cessation. Patients  Thirty-two young overweight polycystic ovary syndrome (PCOS) women matched for age and body mass index (BMI) with other 32 PCOS patients was enrolled. The first group [PCOS-T (trained)] underwent 24-week ET programme, whereas the second [PCOS-DT (detrained)] underwent 12-week ET programme followed by 12-week detraining period. Methods  At baseline, after 12- and 24-week follow-up, all PCOS women were studied for their hormonal (ovarian and adrenal androgens), metabolic (glucose and …

Blood GlucoseSettore MED/09 - Medicina Internaendocrine system diseasescardiopulmonary effectsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOverweightSettore MED/13 - EndocrinologiaBody Mass IndexEndocrinologyInsulinmedicine.diagnostic_testVO2 maxPCOS womenPolycystic ovaryfemale genital diseases and pregnancy complicationsRespiratory Function TestsCholesterolHeart Function Testspolicystic ovary syndromeFemalemedicine.symptomPhysical exercise training cardiovascular function pulmonary function PCOS hyperandrogenism insulin resistanceSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotoriePolycystic Ovary Syndromemedicine.medical_specialtyexercise training programmeLipoproteinsPhysical exerciseOxygen ConsumptionInternal medicinemedicineHumansExercise physiologyExerciseTriglyceridescardiopulmonary functionbusiness.industryInsulinMetabolic effects; cardiopulmonary effects; exercise training programme; PCOS womennutritional and metabolic diseasesOverweightCardiovascular riskSettore MED/11 - Malattie Dell'Apparato CardiovascolareMetabolic effectsEndocrinologystructured exercise training programmebusinessLipid profileBody mass index
researchProduct

ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism

2014

During the past years, targeted therapies for cancer have been developed using drugs that have significant metabolic consequences. Among them, the mammalian target of rapamycin (mTOR) inhibitors and, to a much lesser extent, the tyrosine kinase inhibitors (TKIs) are involved. mTOR plays a key role in the regulation of cell growth as well as lipid and glucose metabolism. Treatment with mTOR inhibitors is associated with a significant increase in plasma triglycerides and LDL cholesterol. mTOR inhibitors seem to increase plasma triglycerides by reducing the activity of the lipoprotein lipase which is in charge of the catabolism of triglyceride-rich lipoproteins. The increase in LDL cholesterol…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and MetabolismAntineoplastic AgentsHypoglycemiaCarbohydrate metabolismBiologyEndocrinologyInsulin resistanceInternal medicineHyperlipidemiamedicineHomeostasisHumansGlucose homeostasisEnzyme InhibitorsTriglyceridesPI3K/AKT/mTOR pathwayLipoprotein lipaseTOR Serine-Threonine KinasesGeneral MedicineProtein-Tyrosine KinasesLipid Metabolismmedicine.diseaseEndocrinologyLDL receptorCarbohydrate MetabolismEuropean Journal of Endocrinology
researchProduct